Phuturdex › Diseases › Retinal Dystrophies
Drugs in development · updated 30 October 2026
Retinal Dystrophies: drugs in development
As of 30 October 2026 there are 8 active clinical trials (recruiting or ongoing, phases I–III) on 8 drugs for retinal Dystrophies. 6 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| QR-1123 | I–II | 1 | NCT04123626 |
| SPVN06 | I–II | 1 | NCT05748873 |
| SPVN20 | I–II | 1 | NCT07807111 |
| VP-001 | I–II | 1 | NCT06852963 |
| DF-003 | I | 1 | NCT06395285 |
| LX107 | Early I | 1 | NCT07063030 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| MetforminRiomet Er®, Glumetza® | I–II | 1 | NCT04545736 |
| DisulfiramAntabuse® | I | 1 | NCT06319872 |
Sorted by most advanced phase and number of active trials.
All 8 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Retinitis pigmentosa 25 drugs
- Usher Syndromes 5 drugs
- Retinal degeneration 15 drugs
- Retinal disease 18 drugs
- Leber congenital amaurosis 10 drugs
- Eye disease 19 drugs
- Cone-rod dystrophy 5 drugs
- Diabetic retinopathy 17 drugs
- Stargardt disease 14 drugs
Broader categories
- Genetic disease 33 drugs
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities 4 drugs
- Eye disease 19 drugs
- Hereditary eye disease 4 drugs
- Retinal disease 18 drugs
- Retinal degeneration 15 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D058499 “Retinal Dystrophies”.